Parnell Pharmaceuticals (OTCMKTS:PARNF) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday.

Shares of Parnell Pharmaceuticals (PARNF) traded up $0.03 during mid-day trading on Friday, reaching $0.49. The company had a trading volume of 22,224 shares, compared to its average volume of 19,429. Parnell Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.50.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/01/parnell-pharmaceuticals-parnf-upgraded-by-valuengine-to-sell.html.

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets.

Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.